Corvus reports Q2 loss; soquelitinib shows early activity in atopic derm, PTCL Phase 3 on track

Corvus Pharmaceuticals, Inc.

2024-Q2 EPS reported -$0.18

Early soquelitinib Phase 1 atopic dermatitis data (3 evaluable patients, 100 mg BID) show clinical activity and cytokine changes consistent with ITK inhibition.
Phase 3 registrational trial for soquelitinib in PTCL to start Q3 2024; updated Phase 1/1b data: 39% ORR (6 CRs, 3 PRs) in 23 evaluable patients.
Cash, cash equivalents and marketable securities $47.2M as of June 30, 2024; Q2 2024 net loss $4.3M vs $6.5M prior year; cash runway into Q4 2025.
Ciforadenant Phase 1b/2 trial in RCC met interim efficacy threshold; enrollment continues. New U.S. patent issued for ciforadenant.
Soquelitinib received Fast Track designation for relapsed/refractory PTCL; FDA pediatric waiver granted for T cell lymphoma indication.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.